acetylleucyl-leucyl-norleucinal has been researched along with sb 216763 in 1 studies
| Studies (acetylleucyl-leucyl-norleucinal) | Trials (acetylleucyl-leucyl-norleucinal) | Recent Studies (post-2010) (acetylleucyl-leucyl-norleucinal) | Studies (sb 216763) | Trials (sb 216763) | Recent Studies (post-2010) (sb 216763) |
|---|---|---|---|---|---|
| 321 | 0 | 53 | 342 | 0 | 225 |
| Protein | Taxonomy | acetylleucyl-leucyl-norleucinal (IC50) | sb 216763 (IC50) |
|---|---|---|---|
| G2/mitotic-specific cyclin-B2 | Homo sapiens (human) | 0.55 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.55 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.55 | |
| Cyclin-A2 | Homo sapiens (human) | 0.269 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.269 | |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | 0.0477 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.0342 | |
| Cyclin-A1 | Homo sapiens (human) | 0.269 | |
| G2/mitotic-specific cyclin-B3 | Homo sapiens (human) | 0.55 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, J; Hung, MC; Jian, W; Meric-Bernstam, F; Mills, GB; Mondesire, WH; Peng, J; Zhang, H | 1 |
1 other study(ies) available for acetylleucyl-leucyl-norleucinal and sb 216763
| Article | Year |
|---|---|
Role of glycogen synthase kinase 3beta in rapamycin-mediated cell cycle regulation and chemosensitivity.
Topics: Aminophenols; Antibiotics, Antineoplastic; Antimanic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cyclin D1; Cysteine Proteinase Inhibitors; Down-Regulation; Drug Resistance, Neoplasm; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Half-Life; Humans; Indoles; Leupeptins; Lithium Chloride; Maleimides; Mitochondria; NF-kappa B; Paclitaxel; Proteasome Inhibitors; Sirolimus | 2005 |